Nuvectis Pharma, Inc. (NASDAQ: NVCT) has announced the pricing of its previously disclosed underwritten public offering of 5 million shares of common stock at $20.00 per share, which is expected to generate gross proceeds of approximately $100 million. The offering includes a 30-day option for underwriters to purchase up to an additional 750,000 shares at the same price, less underwriting discounts and commissions. The transaction is anticipated to close on or about July 1, 2026, subject to customary closing conditions.
The company stated that it intends to utilize the net proceeds to advance the development of its key pipeline programs: NXP100, NXP200, and NXP900. Additionally, funds will support future product candidates, hire additional personnel, cover capital expenditures, and for general corporate purposes. Cantor is acting as the sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners serving as co-managers.
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune complement-related conditions and oncology. Its pipeline includes NXP100, a complement Factor B inhibitor designed for complement-mediated diseases, which has the potential to be a best-in-class, once-daily oral treatment. The oncology candidates include NXP900, an oral small molecule inhibitor targeting the SRC Family of Kinases, and NXP200, a brain-penetrant BRAF inhibitor for various solid tumors, including central nervous system cancers, colorectal cancer, melanoma, and non-small cell lung cancer.
The public offering provides Nuvectis with substantial capital to accelerate its clinical programs and expand its research efforts. The company's focus on niche areas with high unmet medical needs positions it to potentially offer significant treatment advancements. The success of these programs could impact the landscape for complement-mediated diseases and certain cancers, highlighting the importance of this financing event for the company's future trajectory.
